Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy
Diabetes negatively impacts vision and retinal function. However, current therapeutic options for diabetic retinopathy (DR) often present limitations, including targeting specific pathways, short duration of action, and need for frequent injections. Timosaponin AIII (TA-III) exhibited the potential...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Materials & Design |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0264127525002527 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688169265496064 |
|---|---|
| author | Jie Zhang Yu Liu Yu Gong Yanyu Shangguan Pengli Wang Yanlong Bi Yong Xu Bo Tao Bing Li |
| author_facet | Jie Zhang Yu Liu Yu Gong Yanyu Shangguan Pengli Wang Yanlong Bi Yong Xu Bo Tao Bing Li |
| author_sort | Jie Zhang |
| collection | DOAJ |
| description | Diabetes negatively impacts vision and retinal function. However, current therapeutic options for diabetic retinopathy (DR) often present limitations, including targeting specific pathways, short duration of action, and need for frequent injections. Timosaponin AIII (TA-III) exhibited the potential of anti-inflammation, anti-oxidative stress and promoting vascular remodeling abilities from bioinformatics analysis tool. Additionally, polyethylene glycol succinimide succinate [PEG-(SS)2]-human serum albumin (HSA) (Hp) hydrogel, known for its excellent biocompatibility and sustained drug release properties, was employed to encapsulate TA-III to exhibit a long-acting, sustained release profile. In vitro results demonstrated that the TA-III/Hp hydrogel upregulated the expression of vascular endothelial growth factor receptor 2 and zonula occludens-1, while reducing the level of vascular endothelial growth factor A. We further observed a significant reduction in the levels of reactive oxygen species, malondialdehyde, interleukin-1β, interleukin-6, and tumor necrosis factor-α under high glucose conditions by using the TA-III/Hp hydrogel in retinal pigment epithelium cells. Notably, intravitreal delivery of TA-III/Hp hydrogel in the DR mouse model effectively increased retinal thickness and numbers of mature blood vessels, while inhibiting oxidative stress and inflammatory factor levels. In conclusion, intravitreal injection of TA-III/Hp hydrogel facilitates sustained release of TA-III, simultaneously providing anti-inflammatory, antioxidative, and vascular remodeling effects in DR. |
| format | Article |
| id | doaj-art-aef9cbe56cb5471dbf53097199ffd8d7 |
| institution | DOAJ |
| issn | 0264-1275 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials & Design |
| spelling | doaj-art-aef9cbe56cb5471dbf53097199ffd8d72025-08-20T03:22:04ZengElsevierMaterials & Design0264-12752025-05-0125311383210.1016/j.matdes.2025.113832Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathyJie Zhang0Yu Liu1Yu Gong2Yanyu Shangguan3Pengli Wang4Yanlong Bi5Yong Xu6Bo Tao7Bing Li8Department of Ophthalmology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, ChinaDepartment of Ophthalmology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, ChinaDepartment of Radiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, ChinaDepartment of Ophthalmology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, ChinaDepartment of Ophthalmology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, ChinaDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; Department of Plastic and Burn Surgery, the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu 610051, China; Corresponding authors.Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China; Corresponding authors.Department of Ophthalmology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China; Corresponding authors.Diabetes negatively impacts vision and retinal function. However, current therapeutic options for diabetic retinopathy (DR) often present limitations, including targeting specific pathways, short duration of action, and need for frequent injections. Timosaponin AIII (TA-III) exhibited the potential of anti-inflammation, anti-oxidative stress and promoting vascular remodeling abilities from bioinformatics analysis tool. Additionally, polyethylene glycol succinimide succinate [PEG-(SS)2]-human serum albumin (HSA) (Hp) hydrogel, known for its excellent biocompatibility and sustained drug release properties, was employed to encapsulate TA-III to exhibit a long-acting, sustained release profile. In vitro results demonstrated that the TA-III/Hp hydrogel upregulated the expression of vascular endothelial growth factor receptor 2 and zonula occludens-1, while reducing the level of vascular endothelial growth factor A. We further observed a significant reduction in the levels of reactive oxygen species, malondialdehyde, interleukin-1β, interleukin-6, and tumor necrosis factor-α under high glucose conditions by using the TA-III/Hp hydrogel in retinal pigment epithelium cells. Notably, intravitreal delivery of TA-III/Hp hydrogel in the DR mouse model effectively increased retinal thickness and numbers of mature blood vessels, while inhibiting oxidative stress and inflammatory factor levels. In conclusion, intravitreal injection of TA-III/Hp hydrogel facilitates sustained release of TA-III, simultaneously providing anti-inflammatory, antioxidative, and vascular remodeling effects in DR.http://www.sciencedirect.com/science/article/pii/S0264127525002527Diabetic retinopathyTimosaponin AIIIHydrogelAnti-inflammationAnti-oxidative stressVascular remodeling |
| spellingShingle | Jie Zhang Yu Liu Yu Gong Yanyu Shangguan Pengli Wang Yanlong Bi Yong Xu Bo Tao Bing Li Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy Materials & Design Diabetic retinopathy Timosaponin AIII Hydrogel Anti-inflammation Anti-oxidative stress Vascular remodeling |
| title | Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy |
| title_full | Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy |
| title_fullStr | Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy |
| title_full_unstemmed | Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy |
| title_short | Intravitreal injection of TA-III with sustained release to simultaneously impart anti-inflammatory, antioxidative, and vascular remodeling activities in diabetic retinopathy |
| title_sort | intravitreal injection of ta iii with sustained release to simultaneously impart anti inflammatory antioxidative and vascular remodeling activities in diabetic retinopathy |
| topic | Diabetic retinopathy Timosaponin AIII Hydrogel Anti-inflammation Anti-oxidative stress Vascular remodeling |
| url | http://www.sciencedirect.com/science/article/pii/S0264127525002527 |
| work_keys_str_mv | AT jiezhang intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT yuliu intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT yugong intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT yanyushangguan intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT pengliwang intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT yanlongbi intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT yongxu intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT botao intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy AT bingli intravitrealinjectionoftaiiiwithsustainedreleasetosimultaneouslyimpartantiinflammatoryantioxidativeandvascularremodelingactivitiesindiabeticretinopathy |